Please ensure Javascript is enabled for purposes of website accessibility
Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Vaccine being given to young woman by female doctor

Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising

Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.

Warren Buffett - TMF

3 Top Warren Buffett Stocks to Buy and Hold

Invest like the legendary multibillionaire with these three great stocks.

Scientist looking through microscope

Why MacroGenics Stock Is Tanking Today

Investors weren't thrilled with the company's latest clinical data.


3 Explosive Biotech Stocks That Could 10X in 10 Years

They're leaders in therapeutic areas with massive growth potential.

Appeal blocks

Why ChromaDex Stock Is Sinking Today

The company lost a key patent infringement lawsuit but plans to appeal the court decision.

Check boxes

Why Seres Therapeutics Stock Is Soaring Today

The company completed its target enrollment in a pivotal clinical study.

Vaccine being given to teen boy

Why Moderna Stock Is Bouncing Back Today

Investors appear to be buying on the dip after yesterday's sell-off.

Woman drawing big fish about to eat little fish

Why Itamar Medical Stock Is Skyrocketing Today

Zoll Medical plans to acquire the small producer of medical devices.

$1 bill folded into arrow trending up

Why Wall Street Thinks This Dirt Cheap Value Stock Could Soar

It's kind of a boring stock. But analysts think that it could deliver not-so-boring growth.


Should Investors Be Concerned About DermTech?

Be concerned? No. Be patient? Yes.


Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.


Will Pfizer's COVID Vaccine Marketing Push Pay Off?

It could over the long run.

Dollar sign - huge

3 Monster Stocks in the Making to Buy Right Now

Their growth prospects are massive.

Vaccination - doctor and patient

Is COVID Vaccine Efficacy Really Falling?

Some experts are skeptical.

Piggy bank with infinity symbol

3 Dividend Stocks to Buy and Hold Forever

They all have solid dividends plus attractive growth prospects.


Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?

Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema.

Scientists looking through microscopes - Copy

3 Smartest Big Pharma Stocks to Buy in September

You can go big this month with these three pharmaceutical stocks.


Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback

There's a one-word answer: delta.

2 scientists in a lab

2 Biotech Stocks That Are Better Buys Than Moderna

The arguments for these two stocks are compelling.

Vaccine bottle and syringe with blue background

Why Novavax Stock Is Slipping Again Today

A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock.